Search research articles
Contact Us
Filters
Showing results (1-10 of 172) with videos related to
Page
of 18
Sort By:
Blood
|
February 5, 2011
How "immunomodulatory" are IMIDs?
Constantine S Mitsiades
Haematologica
|
April 12, 2005
CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q
Constantine S Mitsiades
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2015
Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway
Constantine S Mitsiades
Cancer Cell
|
May 12, 2016
Tight Junction Protein 1: New Insights into Proteasome Inhibitor Resistance and Myeloma Pathophysiology
Constantine S Mitsiades
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 2, 2009
Molecular profiles of proteasome inhibition in plasma cell dyscrasias
Constantine S Mitsiades
Cold Spring Harbor Perspectives in Medicine
|
September 15, 2020
Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma
Constantine S Mitsiades
Hematology/Oncology Clinics of North America
|
January 26, 2024
Proteasome Inhibitors in Multiple Myeloma: Biological Insights on Mechanisms of Action or Resistance Informed by Functional Genomics
Constantine S Mitsiades
Expert Review of Anticancer Therapy
|
July 9, 2005
Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling
Constantine S Mitsiades, Nicholas Mitsiades
Thyroid : Official Journal of the American Thyroid Association
|
April 7, 2005
Thyroid carcinoma cells and Fas-mediated apoptosis
Constantine S Mitsiades, Nicholas Mitsiades
Lancet (London, England)
|
May 3, 2003
P2X7 polymorphism and chronic lymphocytic leukaemia
Constantine S Mitsiades, Nicholas Mitsiades
Page
of 18
Search research articles
Search
Showing results (1-10 of 172) with videos related to
Sort By:
Page
of 18
Blood
|
February 5, 2011
How "immunomodulatory" are IMIDs?
Constantine S Mitsiades
Haematologica
|
April 12, 2005
CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q
Constantine S Mitsiades
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2015
Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway
Constantine S Mitsiades
Cancer Cell
|
May 12, 2016
Tight Junction Protein 1: New Insights into Proteasome Inhibitor Resistance and Myeloma Pathophysiology
Constantine S Mitsiades
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 2, 2009
Molecular profiles of proteasome inhibition in plasma cell dyscrasias
Constantine S Mitsiades
Cold Spring Harbor Perspectives in Medicine
|
September 15, 2020
Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma
Constantine S Mitsiades
Hematology/Oncology Clinics of North America
|
January 26, 2024
Proteasome Inhibitors in Multiple Myeloma: Biological Insights on Mechanisms of Action or Resistance Informed by Functional Genomics
Constantine S Mitsiades
Expert Review of Anticancer Therapy
|
July 9, 2005
Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling
Constantine S Mitsiades, Nicholas Mitsiades
Thyroid : Official Journal of the American Thyroid Association
|
April 7, 2005
Thyroid carcinoma cells and Fas-mediated apoptosis
Constantine S Mitsiades, Nicholas Mitsiades
Lancet (London, England)
|
May 3, 2003
P2X7 polymorphism and chronic lymphocytic leukaemia
Constantine S Mitsiades, Nicholas Mitsiades
Page
of 18